arrow
J

Jochen K. Lennerz

Harvard University
H指数:73
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unintended consequences of legacy oversight in digital medicine

数字医学中遗留监管的意外后果

2026-05-200
PRE
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images

10种人工智能模型在评估乳腺癌全切片图像中人表皮生长因子受体2(HER2)表达方面的一致性

2026-01-012
PRE
Immune Composition and Immunotherapy Outcomes of Mesothelioma with BAP1, CDKN2A, MTAP, and NF2 Alterations

间皮瘤中BAP1、CDKN2A、MTAP和NF2变异的免疫组成和免疫治疗效果

2025-06-250
PRE
Tumor-immune partitioning and clustering algorithm for identifying tumor-immune cell spatial interaction signatures within the tumor microenvironment

肿瘤-免疫分区与聚类算法:用于识别肿瘤微环境内肿瘤-免疫细胞空间相互作用特征

2025-02-180
OA
Quantifying cell divisions along evolutionary lineages in cancer

量化癌症进化谱系中的细胞分裂

2025-02-042
OA
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

精准肿瘤学中耐药性解码模型:胆管癌对FGFR抑制剂的获得性耐药

2024-12-011
OAAI
Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors

表现为多原发肿瘤的EGFR突变肺癌的发育镶嵌

2024-10-151
OAAI
A vision to the future: value-based laboratory medicine
2024-09-135
PRE
FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy
THYROID
IF6.7
2024-09-012
PRE
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+gastroesophageal adenocarcinoma
2024-08-091
OAAI
Virus-Induced Acute Respiratory Distress Syndrome Causes Cardiomyopathy Through Eliciting Inflammatory Responses in the Heart
2024-07-025
OA